Melissa L. McPheeters

Mar 31, 2024 | psiquiatria.com | Melissa L. McPheeters |Elizabeth O’Connor

El trastorno por consumo de alcohol afecta a más de 28, 3 millones de personas en los Estados Unidos y se asocia con mayores tasas de morbilidad y mortalidad. Objetivo Comparar la eficacia y la eficacia comparativa de las terapias para el trastorno por consumo de alcohol. Fuentes de datos Se realizaron búsquedas en PubMed, la Biblioteca Cochrane, el Registro Cochrane Central d...

Mar 5, 2024 | jamanetwork.com | Melissa L. McPheeters |Elizabeth O’Connor |Daniel E Jonas |Sean Riley

Pharmacotherapy for Alcohol Use Disorder—Reply Pharmacotherapy for Alcohol Use Disorder Melissa McPheeters, PhD, MPH; Elizabeth A. O’Connor, PhD; Sean Riley, MSc, MA; Sara M. Kennedy, MPH; Christiane Voisin, MSLS; Kaitlin Kuznacic, PharmD; Cory P. Coffey, PharmD; Mark D. Edlund, MD, PhD; Georgiy Bobashev, PhD; Daniel E.

Nov 7, 2023 | jamanetwork.com | Melissa L. McPheeters |Elizabeth O’Connor |Sean Riley |Sara Kennedy

Key PointsQuestion  Which pharmacotherapies are associated with improved outcomes for people with alcohol use disorder? Findings  In this systematic review and meta-analysis that included 118 clinical trials and 20 976 participants, 50 mg/d of oral naltrexone and acamprosate were each associated with significantly improved alcohol consumption-related outcomes compared with placebo.

Apr 18, 2023 | pacesconnection.com | Melissa L. McPheeters

It's back! The next iteration of Unlearning Ableism will be on May 18th at 3:30PT/6:30ET. This session is designed to support participants' understanding of what ableism is, how it shows up in our lives, and how to challenge ableism in our practices. We will explore such topics as TL Lewis' working definition of ableism and consider several models of disability.